Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Orig3n was a Boston-based biotechnology company founded in 2014, renowned for its direct-to-consumer DNA testing services and pioneering research in regenerative medicine using induced pluripotent stem cells (iPSCs). The company aimed to empower individuals with genetic insights and advance cellular therapies. Orig3n's core mission revolved around creating the world's largest crowdsourced cell repository to accelerate the future of medicine. The company ceased independent operations following its acquisition by CooperSurgical in August 2021, with its assets and technology subsequently integrated.
Served as the primary center for research and development, laboratory operations, product development, and corporate administration before the company's acquisition.
The facility likely included state-of-the-art laboratory spaces for genetic sequencing and stem cell research, alongside modern office environments designed to foster collaboration and innovation.
Prior to acquisition, Orig3n cultivated an energetic, innovative, and fast-paced startup culture. The environment encouraged scientific curiosity, technological advancement, and a mission-driven approach to personalized medicine and regenerative therapies.
Its location in Boston's Seaport District placed Orig3n at the heart of one of the world's leading biotechnology ecosystems, facilitating access to talent, research institutions, and investment.
During its operational years, Orig3n primarily focused on the United States market for its direct-to-consumer DNA testing kits and services. While its regenerative medicine research held global scientific interest and potential for international collaborations, its direct commercial operations were largely U.S.-centric prior to its acquisition.
27 Drydock Avenue
Boston
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Orig3n' leadership includes:
Orig3n has been backed by several prominent investors over the years, including:
Orig3n was acquired by CooperSurgical in August 2021. As a result, its independent executive team was dissolved as operations were integrated. There have been no new hires or exits pertaining to an independent Orig3n executive team in the last 12 months, as the company ceased to exist in its original form post-acquisition. The information below relates to the leadership transition during the acquisition period.
Discover the tools Orig3n uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition in August 2021, Orig3n likely used common corporate email structures. These email addresses are no longer active as the company's domain is defunct.
A common format was likely [first_initial][last]@orig3n.com or [first].[last]@orig3n.com.
Format
e.g., rsmith@orig3n.com (example, historical and not active)
Example
0%
Success rate
Multiple industry reports & executive LinkedIn profiles (e.g. Robin Y. Smith) • August 2, 2021
Orig3n, Inc. was acquired by CooperSurgical in August 2021. This acquisition led to the integration of Orig3n's genetic testing technologies and regenerative medicine assets into CooperSurgical's portfolio, particularly to enhance its offerings in women's health and fertility....more
Boston Business Journal • October 11, 2018
Boston-based biotech Orig3n Inc. introduced a new line of DNA tests utilizing a cheek swab instead of traditional blood samples. This innovation aimed to make genetic testing more accessible and user-friendly, covering areas like fitness, nutrition, and skin health....more
Xconomy • September 12, 2017
Orig3n raised $12.8 million in a Series A extension round to further develop its induced pluripotent stem cell (iPSC) repository, LifeCapsule, and expand its range of consumer DNA tests. The funding aimed to support R&D and commercialization efforts....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Orig3n, are just a search away.